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Abstract Heart failure (HF)-associated anemia is common
and has a poor outcome. Because bone marrow (BM)
dysfunction may contribute to HF-associated anemia, we
first investigated mechanisms of BM dysfunction in an
established model of HF, the transgenic REN2 rat, which is
characterized by severe hypertrophy and ventricular dilata-
tion and SD rats as controls. Secondly, we investigated
whether stimulation of hematopoiesis with erythropoietin
(EPO) could restore anemia and BM dysfunction. After
sacrifice, erythropoietic precursors (BFU-E) were isolated
from the BM and cultured for 10 days. BFU-E were
quantified and transcript abundance of genes involved in
erythropoiesis were assayed. Number of BFU-E were
severely decreased in BM of REN2 rats compared to SD
rats (50±6.2 vs. 6.4±1.7, p<0.01). EPO treatment in-
creased hematocritintheSD-EPOgroup(after6weeks,49±1
vs. 58±1%, p<0.01); however, in the mildly anemic REN2
rats, there was no effect (43±1 vs. 44±1%). This was
paralleled by a 67% decrease in BFU-E in BM of REN2 rats
compared to SD (p<0.01). EPO significantly improved
BFU-E in both SD and REN2 but could not restore this to
control levels in the REN2 rats. Expression of several genes
involved in differentiation (LMO2), mobilization (SDF-1),
and iron incorporation (transferrin receptor) of the BM were
differentially expressed in REN2 rats compared to SD rats,
and EPO did not normalize this. Altogether, these results
suggest that BM dysfunction is an important contributor to
HF-associated anemia and that EPO is not an effective agent
to treat HF-associated anemia.
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Introduction
Anemia as a co-morbidity in heart failure (HF) is associated
with a poor outcome [1, 2]. The prevalence of anemia in
HF is reported to be over 40% in patients with advanced
HF [3]. The causes of anemia in HF are only partially
understood, although several mechanisms have been impli-
cated [4], including treatment with ACE-inhibitors [5], a
blunted erythropoietin (EPO) production due to renal
dysfunction [6], congestion [7], and iron deficiency [8].
However, these causes only partially explain the severity of
anemia and are difficult to target.
Recent publications pointed towards bone marrow (BM)
dysfunction as a potential contributing factor to anemia in
HF. Iversen et al. showed decreased hematopoiesis in BM
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DOI 10.1007/s00109-010-0710-6in an experimental (murine) model of post-myocardial
infarction HF [9]. Our group recently provided the first
clinical proof for the existence of BM dysfunction in human
ischemic HF [10]. We showed that HF is associated with a
profound and general BM dysfunction, simultaneously
affecting multiple hematopoietic lineages. Very recently,
the group of Iversen provided further evidence that HF is
associated with general BM dysfunction by showing that
anemia occurs in both ischemic and non-ischemic murine
HF models [11]. Apparently, the mechanisms of anemia in
HF are dependent of etiology and are possibly caused by
general HF factors like overproduction of neurohormones
or hypoperfusion [11]. Importantly, data as to whether pro-
erythropoietic therapy could restore anemia and BM
function in HF is lacking.
Therefore, we evaluated the severity and mechanisms of
anemia and BM dysfunction in an established experimental
model of hypertensive HF, the transgenic TGR(mREN2)27
rat. Furthermore, we investigated if stimulation of hemato-
poiesis with EPO administration could restore, at least in
part, HF-associated anemia and BM function. Finally, we
studied in detail well-established factors of erythroid
differentiation (LMO2, GATA-1) and mobilization
(MMP9, SDF-1) (Fig. 1, adapted from Koury et al. [12]).
LMO2 and GATA-1 are both differentiation factors, where
MMP9 mobilizes erythroid precursors from the BM into the
peripheral blood, and SDF-1 is a negative regulator of
erythroid mobilization. Furthermore, we analyzed factors
involved in iron incorporation in the BM (transferrin
receptor and ferroportin, both involved in maintaining
cellular iron homeostasis) and studied if expression of
these factors is changed during EPO administration.
Materials and methods
Animal model
We employed 6-week-old, male, homozygous TGR
(mREN2)27 rats [13]. See “Electronic supplementary
material” for detailed description. Rats were fed with ad
libitum regular chow that contains sufficient amounts of
vitamin B and iron (RMH-B 2181, AB Diets, The
Netherlands). Over the course of the experiment, the
mortality rate of REN2 rats was 20% (as reported;
mortality was 0% for control (Sprague–Dawley, SD) rats).
The experimental protocol was approved by the Animal
Ethical Committee of the University of Groningen, The
Netherlands, and conducted in accordance with existing
guidelines for the care and use of laboratory animals.
Experimental protocol
To stimulate erythropoiesis, rats were randomized to
treatment with the long-acting EPO analogue darbepoetin
alpha (40 μg/kg, Aranesp®, Amgen Inc., Thousand Oaks,
CA, USA) administered subcutaneously every 3 weeks
(baseline, 3 and 6 weeks) or saline (used as control). The
dose of EPO was based on our extensive experience with
this compound and previous data that this dose effectively
raises hematocrit in SD rats [14–19]. Rats were sacrificed at
week 7 of the experimental protocol (when aged 13 weeks).
In total, four groups were studied: SD-PL (placebo; N=12),
REN2-PL (N=12), SD-EPO (N=12), REN2-EPO (N=15).
At baseline, 3 and 6 weeks, blood was drawn from the tail
vein for a full blood count. At sacrifice, we analyzed serum
Fig. 1 Overview of different
factors involved in differentiation
and mobilization during different
stages of erythropoiesis, which
expression was measured (results
shown in Fig. 5). Adapted from
Koury et al. [12], according to
Hanson et al. [29], Ohneda et al.
[31], and Jin et al. [32]. Factors
highlighted in green are positive
regulators, factor highlighted in
red is a negative regulator. HSC
hematopoietic stem cell, BFU-E
burst forming unit-erythroid,
CFU-E colony forming unit-
erythroid, RET reticulocyte, RBC
red blood cell, LMO2 LIM do-
main only 2 protein, TAL T cell
acute lymphocytic leukemia pro-
tein, GATA GATA binding pro-
tein, FOG friend of GATA, MMP
matrix metallopeptidase, SDF
stromal cell-derived factor
378 J Mol Med (2011) 89:377–387iron status. Blood pressure via tail cuff and hemodynamic
data at sacrifice were measured as described [20, 21].
Furthermore, to monitor the development of HF, echocar-
diography was performed at baseline, 3 and 6 weeks. For
details, see “Electronic supplementary material”.
Bone marrow isolation and MACs sorting
BM was isolated from tibia and femurs as previously
described [22]. C-kit positive (c-kit
+) cells were isolated as
described in the “Electronic supplementary material”.
Briefly, the cell pellet was washed twice with PBS to
remove platelets. Cells were labeled with polyclonal rabbit
anti c-kit antibody, followed by goat anti-rabbit IgG
microbeads. Anti c-kit-labeled cells were sorted by using
mini-magnetic activated cell sorting columns in a magnetic
field. Effluent was collected in chilled IMEM medium. C-
kit
+ cells were collected with 1 mL chilled IMEM medium,
and cell number was counted.
Cell proliferation assay
After MACs column sorting, 1×10
4 c-kit
+ BM cells were
plated in 1 mL semi-solid medium (MethoCult, Stem Cell
Technologies, Köln, Germany) in 35 mm Petri dishes in
duplicate. The dishes were incubated at 37 C with 5%
CO2 and 95% humidity for 2 weeks. Colonies were
scored using an inverted phase-controlled microscope
(Leica 090-135002, Leica Microsystems, CMS GmbH,
Germany). Burst-forming units-erythroid (BFU-E) were
defined as consisting of 30 or more cells. Colony-forming
units (CFU) were defined as consisting of 50 or more
cells.
FACS analysis
BM mononuclear cells were harvested from tibia and femur
of experimental animals and frozen in liquid nitrogen with
10% DMSO in medium in assay. FACS analysis was
performed on an LSRII cytometer (BD Biosciences, San
Jose, CA, USA). For phenotypic analysis by flow cytom-
etry, 2–5×10
7 cells were dissolved in 10 mL cold DMEM
with 10% FBS. Cell pellet were resuspended in 80 μL PBS/
0.5% BSA. Samples were subsequently stained with rabbit
polyclonal anti c-kit antibody (1 μg/10
6 cells, Santa Cruz
Biotechnology, Heidelberg, Germany) on ice for 30 min.
After washing twice with 2 mL PBS/0.5% BSA, cells were
incubated with Alexa Fluor® 647 (1 μg/10
6 cells, Invi-
trogen, OR, USA) and FITC rat anti-mouse IgG (1 μg/10
6
cells, BD Biosciences Pharmingen, Breda, The Netherlands)
as secondary antibodies. Cells were then suspended in 0.5 mL
PBS/0.5% BSA and analyzed within 1 h. Unstained cells and
cells stained with second antibody only were used as a
negative control. Data were analyzed by FlowJo software
(V7.5.5, Ashland, OR, USA).
Quantitative real-time PCR
Total RNA from c-kit
+ cells and left ventricular (LV)
tissue was extracted using the Nucleospin RNA II kit,
according to manufacturer’s protocol (Machery-Nagel,
Düren, Germany). cDNA synthesis and quantitative real-
time PCR (RT-qPCR) were performed as previously
described with using 0.5 μgt o t a lR N A[ 23]. mRNA
levels were expressed in relative units based on a standard
curve obtained with serial dilutions of a calibrator cDNA
mixture. To normalize expression data, multiple reference
genes were used as described [24]. Please see “Electronic
supplementary material” for full protocol and list of primers.
Statistical analyses
Results are reported as means±standard errors of the mean.
Number of BFU-E, CFU, and c-kit
+ cells were normalized
to SD-PL group. Statistical analysis among groups was
performed by ANOVA with the Bonferroni post hoc test if
distributed normally or with the Kruskall–Wallis test
followed by Mann–Whitney U test when skewed distribut-
ed. All p values are two-tailed, and a p value of less than
0.05 was considered significant. All analyses were per-
formed using SPSS version 16.0 software (SPSS, Chicago,
IL, USA).
Results
Hypertensive REN2 rats develop heart failure
REN2 and SD rats were treated with or without EPO and
were monitored for 6 weeks and sacrificed at an age of
13 weeks. As expected, REN2 rats suffered from severe
hypertension (Fig. 2), providing the substrate for HF
development. Heart weight (adjusted for tibia length), LV
end diastolic pressure (LVEDP), and atrial natriuretic
peptide (ANP) mRNA expression were all significantly
increased in the REN2-PL and REN2-EPO groups, indic-
ative for HF (Fig. 2). Table 1 shows the hemodynamic data
at sacrifice. Indices of maximal contraction and relaxation
of the LV (dPdtmax and dPdtmin) were both significantly
decreased in the REN2 groups, compared to the SD groups,
indicating development of HF. Cardiac output (CO),
assessed with echo Doppler prior to sacrifice, is decreased
in both REN2 groups compared to the SD groups.
Echocardiographic data during the experiment confirmed
development of LV hypertrophy and LV dilatation in REN2
rats (shown in “Electronic supplementary material”).
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Table 2 shows the full blood count for all experimental
groups at sacrifice. As hypothesized, REN2 rats were
mildly anemic and had mild to moderate reductions of
other hematologic parameters as well (except platelet and
reticulocyte count, which were increased). Administration
of EPO increased hematocrit (Ht) levels significantly in
the SD-EPO group compared to the SD-PL group (57.8±
1.1% vs. 49.3±0.8%, p<0.01); however, EPO adminis-
tration did only marginally increase Ht in the REN2-EPO
group (44.0±0.6% vs. 42.7±0.5%, compared to REN2-
PL, p=NS, Fig. 3). An identical pattern was observed for
hemoglobin levels. Furthermore, RBC, MCV, and MCH
were all significantly decreased in both the REN2-PL and
the REN2-EPO groups, providing further evidence of
anemia. We observed an increased reticulocyte count in
the REN2 groups, which is commonly seen in anemia.
EPO plasma levels increased significantly in all EPO
treated groups (measured with ELISA as before [17], see
“Electronic supplementary material”). Deficiencies of
iron, vitamin B12, and folic acid were ruled out and did
not differ between SD and REN2 groups (see “Electronic
supplementary material”).
Fig. 2 Shows that the used
animal model is a model of
hypertensive heart failure. a
Mean arterial pressure (MAP)
during the experiment. MAP is
significantly higher at all time
points for REN2 groups com-
pared to SD groups. b Heart
weight normalized to tibia
length. c Left ventricular end
diastolic pressure (LVEDP) at
sacrifice. d mRNA expression
of atrial natriuretic peptide
(ANP) in left ventricular tissue.
ANP is expressed as fold
change. HW heart weight, Base
baseline, Wk week, PL placebo.
*p<0.05; **p<0.01
SD-PL (N=12) REN2-PL (N=12) SD-EPO (N=12) REN2-EPO (N=15)
LV weight (mg) 841±15 1,105±44* 809±17 1,157±36**
TL (mm) 38.3±0.3 38.1±0.2 38.6±0.2 38.2±0.3
Body weight (g) 367±6 309±7* 360±8 316±9**
Heart rate (bpm) 352±17 347±12 352±12 350±10
dPdtmax (mmHg/s) 7,993±290 5,625±356* 8,676±618 5,785±295**
dPdtmin (mmHg/s) −9,211±666 −5,730±335* −10,249±711 −6,010±367**
CO (mL/min) 145±4 112±10* 138±6 121±11**
Table 1 Data at sacrifice
Table shows weights and hemo-
dynamic data at sacrifice. Car-
diac output (CO) was assessed
with echo Doppler at sacrifice in
anesthetized animals.
LV left ventricle, TL tibia length,
PL placebo.
*p<0.05 vs. SD-PL; **p<0.05
vs. SD-EPO
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To provide mechanistic insight into the causes of anemia,
we studied the number of BFU-E and CFU colonies with a
cell proliferation assay (Fig. 3b, c). REN2 rats (treated with
placebo) had a severely decreased number of BFU-E
colonies, compared to SD-PL (0.33±0.11-fold, normalized
to SD-PL, p<0.05). This indicates either a reduced number
or a limited proliferation capacity of erythroid precursors in
the BM. EPO administration increased the number of BFU-E
colonies, both in the SD-EPO group (1.92±0.33-fold vs. SD-
PL, p<0.05) as well as in the REN2-EPO group, albeit much
less (0.88±0.21-fold vs. SD-PL, p<0.05).
Todissectabnormalitiesintheerythroidprecursorsonlyfrom
generalabnormalitiesintheBM,wealsoinvestigatednumberof
CFU colonies. Number of CFU is only slightly, but significantly
decreased in the REN2-PL group compared to SD-PL group.
Low levels of hematopoietic stem cells in REN2 rats
To confirm the findings in the cell proliferation assay, we
performed FACS analysis of c-kit
+ cells in BM (Fig. 4).
Compared to SD-PL, the number of c-kit
+ cells is reduced
in REN2-PL (with 43%, p<0.05). In line with the BFU-E
cell proliferation assay number, EPO treatment increased
the number of c-kit
+ cells measured by FACS in both the
SD-EPO group (1.6-fold, p<0.05 vs. SD-PL) and the
REN2-EPO group (to baseline, vs. SD-PL, p=NS). However,
the response to EPO was less strong in the REN2 rats.
mRNA expression of factors involved in erythroid
differentiation, mobilization, and iron incorporation
LMO2 was significantly reduced in the REN2-PL group
(34% vs. SD-PL, p<0.05). EPO treatment reduced the
Fig. 3 a Change in hematocrit (Ht) levels during experiment. EPO
administration cannot increase Ht levels in REN2 rats. b Number of
burst forming units-erythroid (BFU-E, normalized to SD-PL). c
Number of colony forming units (CFU, normalized to SD-PL). PL
placebo, BM bone marrow, Wk week, #p<0.05 vs. SD-PL, REN2-PL
and REN2-EPO, ¶p<0.05 vs. REN2-PL and REN2-EPO, *p<0.05,
**p<0.01
Table 2 Hematology
SD-PL (N=12) REN2-PL (N=12) SD-EPO (N=12) REN2-EPO (N=15)
Hb (mmol/L) 9.6±0.8 9.0±0.1 12.4±0.2* 9.3±0.1***
Ht (%) 49.3±0.8 42.7±0.5* 57.8±1.1* 44.0±0.6***
WBC (×10
9/L) 14.6±0.5 11.4±0.3* 14.8±0.6 11.6±0.5***
RBC (×10
12/L) 8.8±0.2 8.0±0.1* 9.8±0.2* 8.0±0.1***
PLT (×10
9/L) 522±32 744±33* 485±36 711±25***
RET (promille) 27.5±6.1 31.1±2.4* 7.0±1.4* 33.2±2.7***
MCV (fl) 57.0±0.7 53.2±0.3* 58.2±1.2 54.8±0.4**; ***
MCH (atto mol) 1,204±8 1,127±12* 1,247±20* 1082±83***
MCHC (mmol/L) 21.1±0.2 21.2±0.2 21.5±0.2 22.2±1.0
Table shows full blood count at sacrifice.
Hb hemoglobin, Ht hematocrit, WBC white blood cell count, RBC red blood cell count, PLT platelet count, RET reticulocytes, MCV mean
corpuscular volume, MCH mean corpuscular hemoglobin, MCHC mean corpuscular hemoglobin concentration, PL placebo.
*p<0.05 vs. SD-PL; **p<0.05 vs. REN2-PL; ***p<0.05 vs. SD-EPO
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increase the LMO2 expression in the REN2-EPO group.
Vice versa, expression of GATA-1 was 2.3-fold increased in
the REN2-PL group compared to the SD-PL group (p<
0.01). Treatment with EPO increased the GATA-1 expres-
sion in the SD-EPO group, but did not affect the GATA-1
expression in the REN2-EPO group. These data suggest
that differentiation of erythrocyte-like BM precursors is
inhibited in HF and that EPO treatment partially restores
this (Fig. 5).
Expression of MMP9 was reduced with 60% in the
REN2-PL group compared to the SD-PL group (p<0.05).
Treatment with EPO did not exert substantial effects on
MMP9 expression in neither SD nor REN-2 rats. In
contrast, SDF-1 expression was significantly increased in
the REN2-PL group (3.5-fold vs. SD-PL, p<0.05). Treat-
Fig. 4 a–d Typical examples of FACS analysis. Every dot is a single
cell count. The x-axis (Comp-APC-A) is the gate for fluorescent cells,
the y-axis (SSC-A) is the cell size. Red color is high density of cell
count; blue color is lower density of cell count. e Number of the
erythroid c-kit
+ cells in bone marrow. PL placebo, BM bone marrow.
*p<0.05; **p<0.01
382 J Mol Med (2011) 89:377–387Fig. 5 mRNA expression of
different factors involved in dif-
ferentiation (a, b) and mobiliza-
tion (c, d) of c-kit
+ cells. mRNA
expression of different factors
involved in iron metabolism (e,
f). LMO2 LIM domain only 2
protein, GATA-1 GATA binding
protein, MMP9 matrix metallo-
peptidase, SDF-1 stromal cell-
derived factor, PL placebo.
*p<0.05; **p<0.01
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(5.6-fold vs. SD-EPO, p<0.01). These data suggest that
mobilization of erythrocyte-like BM precursors is inhibited
in HF and that this cannot be restored by EPO treatment.
mRNA expression of ferroportin was not statistically
different between the four groups, albeit that ferroportin is
slightlylessexpressedinbothREN2groups.mRNAexpression
of transferrin receptor was comparable between the SD-PL vs.
REN2-PL groups (1.6±0.2-fold vs. SD-PL, p=NS). However,
after treatment with EPO, the expression of transferrin receptor
was increased in the SD-EPO group (2.8±0.7-fold vs. SD-PL,
p<0.05), where the expression was not increased in the
REN2-EPO group, indicating a reduction in iron incorporation
in the erythroid cells in REN2 rats after EPO administration.
Discussion
In hypertensive REN2 rats with progressive HF, we
observed mild anemia and a profound dysfunction of the
erythroid lineage in the BM. Treatment with EPO with
the aim to rescue this anemia did not diminish the
anemia. Apparently, HF-associated BM dysfunction is a
rather complex phenomenon that may require other
treatment options. In concert with this, we observed that
along the entire line of maturation of the erythroid
lineage, multiple genes associated with differentiation,
mobilization, and iron incorporation were abnormally
expressed in BM from HF rats. Figure 6 provides an
overview of the mechanisms of BM dysfunction involved
in HF-associated anemia.
We used a monogenetic rat model with overexpression
of the renin gene, resulting in hypertension and concomi-
tant HF development. These rats also develop mild anemia,
which is in line with the observations of Iversen et al., who
described for the first time the existence of HF-associated
anemia in mice [9]. Our results extend this observation of
Iversen to another species (rat) and moreover show that this
also occurs in animals in which hypertension is the sole
source for HF development.
Fig. 6 Schematic overview of the mechanisms of bone marrow
dysfunction involved in HF-associated anemia. Different triggers of
anemia in heart failure such as insensitivity of EPO, iron deficiency,
and neurohormonal activation have a negative effect on the hemato-
poietic stem cells in the bone marrow. Furthermore, impaired
proliferation, differentiation, mobilization, and iron incorporation in
hematopoietic stem cells contribute to the bone marrow dysfunction,
causing anemia and adding to the heart failure syndrome, which in
turn triggers anemia in heart failure, etc. EPO treatment does not
rescue the dysfunction of the erythroid lineage and does not improve
heart failure-associated anemia. SNS sympathetic nervous system, RAS
renin–angiotensin system
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prognosis in humans [1–3, 25], we tried to restore this by
EPO treatment. As expected, EPO treatment resulted in a
clear increase in Ht in the control rats. Surprisingly,
however, EPO did not rescue anemia in the REN2 rats
and only showed marginal effects on Ht values. Since the
main action of EPO is the regulation of erythropoiesis, this
is apparently not the single culprit in HF-associated anemia.
Several clinical observations from our group suggested that
EPO levels in HF are disconcordant with the (expected)
levels of hemoglobin [26–28], and our current observations
that EPO cannot rescue HF-associated anemia are in
concert with this. This misbalance between EPO and
hemoglobin levels is related to an increased mortality risk.
Mechanistically, this may be explained by a diminished
response of the BM to high plasma EPO levels in HF, a
phenomenon we confirm in our present study. Together,
this indicates that in HF-associated anemia other treatment
options will be needed.
To obtain further insight in the cause of this anemia, we
analyzed the BM. We observed a profound (43%) decrease
in BM hematopoietic progenitor cells (c-kit
+ cells) in REN2
rats as compared to control animals. This is in line with the
observation of Iversen et al., who observed a reduction of
up to 60% of similar CD34+ cells in mice with HF [9].
Although not investigated in our rat model, they suggested
that the mechanisms of HF-associated anemia may depend
on the etiology of the cardiac disease, where inflammation
seems to be dominant in ischemic HF, while neurohormonal
factors seem to be the player in non-ischemic HF [11].
To further characterize BM dysfunction and the irre-
sponsiveness to EPO in the REN2 rat model of HF, we
performed RT-qPCR analysis to measure the expression of
markers of differentiation (LMO2, GATA-1) and mobiliza-
tion (MMP9, SDF-1) of the erythroid lineage and incorpo-
ration of iron in these cells (ferroportin, transferrin receptor)
(Fig. 5). LMO2, a positive regulator of erythroid differen-
tiation [29], was down-regulated in the REN2-PL group,
which may contribute to the decreased number of BFU-E.
GATA-1 is a transcription factor playing a key role in gene
regulation during erythroid differentiation [30]. This factor
is strictly controlled during development and differentiation
of erythroid cells and essential for the survival of erythroid
progenitors [31]. GATA-1 mRNA expression is 2.3-fold
increased in our experiments in the REN2-PL group,
indicating that survival of the erythroid progenitors is
promoted in this weakened erythropoietic system.
Furthermore, impaired mobilization of erythroid progen-
itors from the BM could contribute to the lack of increase in
Ht upon EPO stimulation. Degradation of BM SDF-1 by
MMP9 contributes to increased mobilization of erythroid
progenitors [32]. So, decreased levels of MMP9, which
result in increased levels of BM SDF-1, could in turn lead
to impaired mobilization of erythroid progenitors from the
BM in REN2 rats.
Analysis of factors involved in iron transportation
yielded some interesting results. mRNA expression of
ferroportin, involved in iron transportation from inside of
a cell to the outer surface, was not different between any
group. mRNA expression of transferrin receptor, involved
in maintaining cellular iron homeostatis, was comparable
between the SD-PL vs. REN2-PL groups. However, after
treatment with EPO, expression was increased in the SD-
EPO group, where expression was not increased in the
REN2-EPO group. We speculate that the lower expression
of transferrin receptor in REN2 rats treated with EPO is
associated with lesser iron incorporation in erythroid cells,
which may explain in part the lesser response to EPO. In
general, we observed a changed expression profile of genes
involved in differentiation, mobilization, and incorporation
of iron in BM.
Besides defects in the erythropoietic lineage of the BM
(reduction in c-kit
+ cells and BFU-E), we also observed a
reduction in number of CFU (with 27%) compared to
control animals. EPO treatment did not improve these
values in the REN2 rats. We recently showed that human
HF is associated with a profound and general BM
dysfunction, simultaneously affecting multiple hematopoi-
etic lineages [10]. Since all these patients obtained optimal
HF-treatment and were obviously more heterogeneous, our
confirmation in this monogenetic rat model further con-
firms these observations in a human population and show
that it is treatment independent. Moreover, HF-associated
anemia appears to be a general phenomenon in mammals.
dPdtmax, dPdtmin, and CO were all significantly
decreased in the REN2 groups compared to the SD groups,
indicating development of HF. Hypoperfusion of the bone
marrow by reduced CO could potentially affect erythropoi-
esis in HF [8]. However, we believe that hypoperfusion is
not (yet) a critical factor, as we have sacrificed the REN2
rats before overt (decompensated) HF had ensued.
Because the REN2 transgene is expressed ubiquitously
and thus also in the hematopoietic cells, we cannot exclude
that the effects of the transgene mediate the phenotype at
least to some extent. However, the sequel of events in the
development of HF in the REN2 rat (hypertrophy, diastolic
dysfunction, systolic dysfunction, overt HF, death) are very
much alike the human situation. Furthermore, the mild
anemia and bone marrow dysfunction associated with HF in
the REN2 rat are also comparable to what we observed in
earlier human studies. So, although this model (like any
rodent model) has limitations, the phenotype we study
herein is, at least to a large extent, comparable to the human
situation.
In conclusion, in REN2 rats with progressive HF, there is
mild anemia and a profound dysfunction of the erythroid
J Mol Med (2011) 89:377–387 385lineage of the BM. Response to EPO is diminished in
REN2 rats and does not rescue the dysfunction of the
erythroid lineage. Multiple genes appear to be involved
in this process. This does, however, not exclude EPO as
a treatment option in HF, because we and others have
shown that EPO has also direct positive effects on the
heart, including anti-apoptotic, pro-angiogenic, and anti-
ischemic actions [14–19]. Therefore, EPO can be benefi-
cial in HF but does not improve HF-associated anemia.
The latter probably needs a more complex treatment
regimen.
Acknowledgements We thank Inge Baudoin, Bianca Meijeringh,
and Linda van Genne for their expert technical assistance.
Funding This study was funded in part by grants from the
Netherlands Organization for Scientific Research (VENI 016-106-
117) and Netherlands Heart Foundation (Grant 2007T046).
Conflicts of interest The authors declare no competing financial
interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1 .A n a n dI ,M c M u r r a yJ J ,W h i t m o r eJ ,W a r r e nM ,P h a mA ,
McCamish MA, Burton PB (2004) Anemia and its relation-
ship to clinical outcome in heart failure. Circulation 110:149–
154
2. O’Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC,
Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J et al
(2006) Clinical correlates and consequences of anemia in a broad
spectrum of patients with heart failure: results of the Candesartan
in Heart Failure: Assessment of Reduction in Mortality and
Morbidity (CHARM) Program. Circulation 113:986–994
3. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J,
Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia
and mortality in heart failure patients: a systematic review and
meta-analysis. J Am Coll Cardiol 52:818–827
4. Westenbrink BD, de Boer RA, Voors AA, van Gilst WH, van
Veldhuisen DJ (2008) Anemia in chronic heart failure: etiology
and treatment options. Curr Opin Cardiol 23:141–147
5. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM,
Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van
Gilst WH (2005) Levels of hematopoiesis inhibitor N-acetyl-seryl-
aspartyl-lysyl-proline partially explain the occurrence of anemia in
heart failure. Circulation 112:1743–1747
6. Pfeffer MA (2008) Anemia treatment in chronic kidney disease:
shifting uncertainty. Heart Fail Rev 13:425–430
7. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E,
Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ (2007)
Anaemia in chronic heart failure is not only related to impaired
renal perfusion and blunted erythropoietin production, but to fluid
retention as well. Eur Heart J 28:166–171
8. Anker SD, Comin Colet J, Filippatos G, Willenheimer R,
Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W,
Niegowska J et al (2009) Ferric carboxymaltose in patients with
heart failure and iron deficiency. N Engl J Med 361:2436–2448
9. Iversen PO, Woldbaek PR, Tonnessen T, Christensen G (2002)
Decreased hematopoiesis in bone marrow of mice with congestive
heart failure. Am J Physiol Regul Integr Comp Physiol 282:
R166–R172
10. Westenbrink BD, Voors AA, de Boer RA, Schuringa JJ,
Klinkenberg T, van der Harst P, Vellenga E, van Veldhuisen DJ,
van Gilst WH (2010) Bone marrow dysfunction in chronic heart
failure patients. Eur J Heart Fail 12:676–684
11. Iversen PO, Andersson KB, Finsen AV, Sjaastad I, von Lueder
TG, Sejersted OM, Attramadal H, Christensen G (2010) Separate
mechanisms cause anemia in ischemic vs. nonischemic murine
heart failure. Am J Physiol Regul Integr Comp Physiol 298:R808–
R814
12. Koury MJ, Sawyer ST, Brandt SJ (2002) New insights into
erythropoiesis. Curr Opin Hematol 9:93–100
13. de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer
AJ, Boomsma F, van Gilst WH, van Veldhuisen DJ, Pinto YM
(2004) Extracellular signal regulated kinase and SMAD signaling
both mediate the angiotensin II driven progression towards overt
heart failure in homozygous TGR(mRen2)27. J Mol Med 82:678–
687
14. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus
KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2004)
Timing of erythropoietin treatment for cardioprotection in ischemia/
reperfusion. J Cardiovasc Pharmacol 44:473–479
15. vanderMeerP,LipsicE,HenningRH,BoddeusK,vanderVeldenJ,
Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG
(2005) Erythropoietin induces neovascularization and improves
cardiac function in rats with heart failure after myocardial infarction.
J Am Coll Cardiol 46:125–133
16. van der Meer P, Lipsic E, Henning RH, de Boer RA, Suurmeijer
AJ, van Veldhuisen DJ, van Gilst WH (2004) Erythropoietin
improves left ventricular function and coronary flow in an
experimental model of ischemia–reperfusion injury. Eur J Heart
Fail 6:853–859
17. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P,
Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van
Veldhuisen DJ, van Gilst WH et al (2007) Erythropoietin
improves cardiac function through endothelial progenitor cell
and vascular endothelial growth factor mediated neovascularization.
Eur Heart J 28:2018–2027
18. Westenbrink BD, Ruifrok WP, Voors AA, Tilton RG, van
Veldhuisen DJ, Schoemaker RG, van Gilst WH, de Boer RA
(2010) Vascular endothelial growth factor is crucial for
erythropoietin-induced improvement of cardiac function in heart
failure. Cardiovasc Res 87:30–39
19. Westenbrink BD, Oeseburg H, Kleijn L, van der Harst P, Belonje
AM, Voors AA, Schoemaker RG, de Boer RA, van Veldhuisen
DJ, van Gilst WH (2008) Erythropoietin stimulates normal
endothelial progenitor cell-mediated endothelial turnover, but
attributes to neovascularization only in the presence of local
ischemia. Cardiovasc Drugs Ther 22:265–274
20. Feng M, Whitesall S, Zhang Y, Beibel M, D’Alecy L, DiPetrillo K
(2008) Validation of volume-pressure recording tail-cuff blood
pressure measurements. Am J Hypertens 21:1288–1291
21. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA
(2008) Measurement of cardiac function using pressure-volume
conductance catheter technique in mice and rats. Nat Protoc
3:1422–1434
22. Wang Y, Qian C, Roks AJ, Westermann D, Schumacher SM,
Escher F, Schoemaker RG, Reudelhuber TL, van Gilst WH,
Schultheiss HP et al (2010) Circulating rather than cardiac
386 J Mol Med (2011) 89:377–387angiotensin-(1–7) stimulates cardioprotection after myocardial
infarction. Circ Heart Fail 3:286–293
23. Kuipers I, van der Harst P, Kuipers F, van Genne L, Goris M,
Lehtonen JY, van Veldhuisen DJ, van Gilst WH, de Boer RA
(2010) Activation of liver X receptor-alpha reduces activation of
the renal and cardiac renin–angiotensin–aldosterone system. Lab
Invest 90:630–636
24. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy
N, De Paepe A, Speleman F (2002) Accurate normalization
of real-time quantitative RT-PCR data by geometric averag-
ing of multiple internal control genes. Genome Biol 3:
research0034
25. Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is
common in heart failure and is associated with poor outcomes:
insights from a cohort of 12 065 patients with new-onset heart
failure. Circulation 107:223–225
26. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH,
van Veldhuisen DJ (2004) Prognostic value of plasma erythropoi-
etin on mortality in patients with chronic heart failure. J Am Coll
Cardiol 44:63–67
27. van der Meer P, Lok DJ, Januzzi JL, de la Porte PW, Lipsic E, van
Wijngaarden J, Voors AA, van Gilst WH, van Veldhuisen DJ (2008)
Adequacy of endogenous erythropoietin levels and mortality in
anaemic heart failure patients. Eur Heart J 29:1510–1515
28. Belonje AM, Voors AA, van der Meer P, van Gilst WH, Jaarsma
T, van Veldhuisen DJ (2010) Endogenous erythropoietin and
outcome in heart failure. Circulation 121:245–251
29. HanssonA, Zetterblad J,van DurenC,AxelsonH,Jonsson JI(2007)
The Lim-only protein LMO2 acts as a positive regulator of erythroid
differentiation. Biochem Biophys Res Commun 364:675–681
30. Kaneko H, Shimizu R, Yamamoto M (2010) GATA factor
switching during erythroid differentiation. Curr Opin Hematol
17:163–168
31. Ohneda K, Yamamoto M (2002) Roles of hematopoietic tran-
scription factors GATA-1 and GATA-2 in the development of red
blood cell lineage. Acta Haematol 108:237–245
32. Jin F, Zhai Q, Qiu L, Meng H, Zou D, Wang Y, Li Q, Yu Z, Han J,
Li Q et al (2008) Degradation of BM SDF-1 by MMP-9: the role
in G-CSF-induced hematopoietic stem/progenitor cell mobiliza-
tion. Bone Marrow Transplant 42:581–588
J Mol Med (2011) 89:377–387 387